Peroxisome proliferator-activated receptor-γ: Too much of a good thing causes harm

EMBO Reports

Volumn 5, Issue 2, 2004, Pages 142-147

  Cock, Terrie Anne ^a   Houten, Sander M ^a   Auwerx, Johan ^a,b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

Atherosclerosis; Integrated metabolism; Longevity; Mouse models; Obesity

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; FATTY ACID; INSULIN; LIGAND; NC 2100; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

AGING; ATHEROSCLEROSIS; CALORIC RESTRICTION; DIABETES MELLITUS; DRUG EFFICACY; ENERGY CONSERVATION; FAT INTAKE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; HEART PROTECTION; HUMAN; INSULIN SENSITIVITY; LIFESTYLE; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW;

ADIPOSE TISSUE; AGING; ANIMALS; ARTERIOSCLEROSIS; CALORIC RESTRICTION; FATS; GENE EXPRESSION; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LONGEVITY; METABOLIC DISEASES; MICE; MUTATION; OBESITY; PPAR GAMMA;

EID: 1642446053     PISSN: 1469221X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.embor.7400082     Document Type: Review

References (64)

1. Agarwal AK, Garg A (2002) A novel heterozygous mutation in PPARγ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87: 408-411
2. Aldhahi W, Hamdy O (2003) Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 3: 293-298
3. Altshuler D et al (2000) The common PPARγ Pro12AIa polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26: 76-80
4. Auwerx J (1999) PPARγ, the ultimate thrifty gene. Diabetologia 42: 1033-1049
5. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM (1999) PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4: 585-595
6. Barroso I et al (1999) Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883
7. Bluher M, Kahn BB, Kahn CR (2003) Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299: 572-574
8. Burdge GC, Jones AE, Frye SM, Goodson L, Wootton SA (2003) Effect of meal sequence on postprandial lipid, glucose and insulin responses in young men. Eur J Clin Nutr 57: 1536-1544
9. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7: 48-52
10. Chen Z et al (2001) Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21: 372-377
11. Claudel T et al (2001) Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 98: 2610-2615
12. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21: 365-371
13. Combs TP et al (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: A potential mechanism of insulin sensitization. Endocrinology 143: 998-1007
14. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ (2003) Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 107: 2548-2550
15. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J (1998) A Pro12AIa substitution in the human PPARγ2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 20: 284-287
16. Friedman JM (2003) A war on obesity, not the obese. Science 299: 856-858
17. Fukui Y, Masui S, Osada S, Umesono K, Motojima K (2000) A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAγ obese mice. Diabetes 49: 759-767
18. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML (2003) Liver PPARγ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278: 34268-34276
19. Guarente L (2000) Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 14: 1021-1026
20. Harrison DE, Archer JR, Astle CM (1984) Effects of food restriction on aging: Separation of food intake and adiposity. Proc Natl Acad Sci USA 81: 1835-1838
21. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM (2003) Adipose-specific PPARγ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 9: 1491-1497
22. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T (2002) PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51: 3586-3590
23. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J (2003) Muscle-specific PPARγ deletion causes insulin resistance. Nat Med 9: 1491-1497
24. Hu E, Kim JB, Sarraf P, Spiegelman BM (1996) Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ. Science 274: 2100-2103
25. Jiang C, Ting AT, Seed B (1998) PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
26. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y (2001) Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86: 3452-3456
27. Koubova J & Guarente L (2003) How does calorie restriction work? Genes Dev 17: 313-321
28. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, Auwerx J (2003) Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice. Proc Natl Acad Sci USA 100: 14457-14462
29. Kubota N et al (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4: 597-609
30. Lane MA, Black A, Handy A, Tilmont EM, Ingram DK, Roth GS (2001) Caloric restriction in primates. Ann NY Acad Sci 928: 287-295
31. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000) PPARγ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531
32. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J (1998) Macrophages in human atheroma contain PPARγ: Differentiation-dependent PPARγ expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol 153: 17-23
33. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B, Reitman ML, Gonzalez FJ (2003) Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111: 737-747
34. Miles PD, Barak Y, He W, Evans RM, Olefsky JM (2000) Improved insulin-sensitivity in mice heterozygous for PPARγ deficiency. J Clin Invest 105: 287-292
35. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW (2001) The role of PPARγ in macrophage differentiation and cholesterol uptake. Nat Med 7: 41-47
36. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti JR (2000) A selective PPARγ modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14: 1425-1433
37. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93: 229-240
38. Nemoto S, Finkel T (2002) Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295: 2450-2452
39. Norman RA, Thompson DB, Foroud T, Garvey WT, Bennett PH, Bogardus C, Ravussin E (1997) Genomewide search for genes influencing percent body fat in Pima indians: Suggestive linkage at chromosome 11Q21 Q22. Am J Hum Genet 60: 166-173
40. Norris AW et al (2003) Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112: 608-618
41. Picard F, Auwerx J (2002) PPARγ and glucose homeostasis. Annu Rev Nutr 22: 167-197
42. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MA (2003) Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev Cell 5: 657-663
43. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA (1998) A potent antidiabetic thiazolidinedione with unique PPARγ-activating properties. J Biol Chem 273: 32679-32684
44. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS (2002) PPARγ knockdown by engineered transcription factors: Exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 16: 27-32
45. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The PPARγ is a negative regulator of macrophage activation. Nature 391: 79-82
46. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY (2003) Alanine for proline substitution in the PPARγ2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23: 859-863
47. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W (2002) A new selective PPARγ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16: 2628-2644
48. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR (1998) Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 339: 953-959
49. Rocchi S et al (2001) A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8: 737-747
50. Rosen ED et al (2003) Targeted elimination of PPARγ in β-cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 23: 7222-7229
51. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM (1999) PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617
52. Rosen ED, Spiegelman BM (2001) PPARγ: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734
53. Sanders TA (2003) Dietary fat and postprandial lipids. Curr Atheroscler Rep 5: 445-451
54. Savage DB et al (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 52: 910-917
55. Sekiya M, Suzuki J, Watanabe K, Funada J, Otani T, Akutsu H (2001) Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus. Jpn Circ J 65: 487-490
56. Smith BA, Edwards MS, Ballachey BE, Cramer DA, Sutherland TM (1991) Body weight and longevity in genetically obese and non-obese mice fed fat-modified diets. Growth Dev Aging 55: 81-89
57. Sohal RS, Weindruch R (1996) Oxidative stress, caloric restriction, and aging. Science 273: 59-63
58. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K (2000) Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 36: 1529-1535
59. Tatar M, Bartke A, Antebi A (2003) The endocrine regulation of aging by insulin-like signals. Science 299: 1346-1351
60. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156
61. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-252
62. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ, DiStefano PS, Chiang LW, Greenberg ME (2002) DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296: 530-534
63. Weindruch RA, Walford RL (1988) The Retardation of Aging and Disease by Caloric Restriction. CC Thomas, Springfield, Illinois, USA
64. Yamauchi T et al (2001) Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108: 1001-1013